These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1370445)

  • 1. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase.
    Dueweke TJ; Kézdy FJ; Waszak GA; Deibel MR; Tarpley WG
    J Biol Chem; 1992 Jan; 267(1):27-30. PubMed ID: 1370445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.
    Tramontano E; Cheng YC
    Biochem Pharmacol; 1992 Mar; 43(6):1371-6. PubMed ID: 1373283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
    Mellors JW; Dutschman GE; Im GJ; Tramontano E; Winkler SR; Cheng YC
    Mol Pharmacol; 1992 Mar; 41(3):446-51. PubMed ID: 1372083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
    Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
    J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
    Nunberg JH; Schleif WA; Boots EJ; O'Brien JA; Quintero JC; Hoffman JM; Emini EA; Goldman ME
    J Virol; 1991 Sep; 65(9):4887-92. PubMed ID: 1714522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme.
    Fletcher RS; Syed K; Mithani S; Dmitrienko GI; Parniak MA
    Biochemistry; 1995 Apr; 34(13):4346-53. PubMed ID: 7535561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
    Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.
    Althaus IW; Chou JJ; Gonzales AJ; Deibel MR; Chou KC; Kezdy FJ; Romero DL; Aristoff PA; Tarpley WG; Reusser F
    J Biol Chem; 1993 Mar; 268(9):6119-24. PubMed ID: 7681060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
    Spence RA; Kati WM; Anderson KS; Johnson KA
    Science; 1995 Feb; 267(5200):988-93. PubMed ID: 7532321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.
    Rodgers DW; Gamblin SJ; Harris BA; Ray S; Culp JS; Hellmig B; Woolf DJ; Debouck C; Harrison SC
    Proc Natl Acad Sci U S A; 1995 Feb; 92(4):1222-6. PubMed ID: 7532306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
    Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B
    Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
    Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
    Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
    Debyser Z; Pauwels R; Andries K; Desmyter J; Engelborghs Y; Janssen PA; De Clercq E
    Mol Pharmacol; 1992 Jan; 41(1):203-8. PubMed ID: 1370707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
    Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
    Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity labeling and functional analysis of the primer binding domain of HIV-1 reverse transcriptase.
    Andreola ML; Tarrago-Litvak L; Levina AS; Kolocheva TI; el Dirani-Diab R; Jamkovoy VI; Khalimskaya NL; Barr PJ; Litvak S; Nevinsky GA
    Biochemistry; 1993 Apr; 32(14):3629-37. PubMed ID: 7682110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
    Starnes MC; Cheng YC
    Virus Genes; 1989 May; 2(3):241-51. PubMed ID: 2474897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
    Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
    Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
    Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
    J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.